RxDoctor Payments Data

Catherine Bennett

Family · Belleville, ILNPI 1427504042

Payments from drug & device makers

$9,153in general payments, 2019–2025

Across 474 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Jazz Pharmaceuticals Inc.$844
  • Regeneron Healthcare Solutions, Inc.$684
  • Harmony Biosciences LLC$658
  • Sanofi$635
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$8,95598%
  • Education$1982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,153 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$60,284
Medicare patients
670
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SunosiSolriamfetol Hcl16$19,358
Breo ElliptaFluticasone/Vilanterol16$10,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,500
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,942
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,594
Albuterol Sulfate HfaAlbuterol Sulfate63$1,585
Armodafinil14$1,308
Modafinil23$822
Ropinirole Hcl59$523
Eszopiclone18$295
Montelukast Sodium18$292
Methylphenidate Hcl12$287
Ipratropium Bromide12$262
Zolpidem Tartrate23$184
Fluticasone Propionate12$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$1,165$26,22145 claims
Axsome Therapeutics, Inc.Sunosi$361$19,35816 claims
AstraZenecaBreztri Aerosphere$1,872$8,94214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Belleville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →